Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas

Learn more about:
Related Clinical Trial
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Toxicity of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) Mechanism of Action of Transcranial Direct Current Stimulation in Neurofibromatosis Type 1 Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults With Neurofibromatosis Type 1 Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas Systematically Assessing Changes in Plexiform Neurofibroma Related Disfigurement From Photographs of Subjects With Neurofibromatosis Type 1 on a Phase 2 Clinical Trial Pilot Randomized Control Trial of Telehealth Group for Improving Peer Relationships (PEERS) in NF1 Open Trial of Telehealth Group for Improving Peer Relationships (PEERS) in NF1 Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) Innovation in the Treatment of Persistent Pain in Adults With NF1: Implementation of the iCanCope Mobile Application- Clinical Trial Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1 Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1 A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) Analysis of Data Collected From Individuals Administered Neurobehavioral Assessments Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia Comparison of Gastrointestinal Motility in Healthy Children and Children With Constipation AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas Medical Treatment of “High-Risk” Neurofibromas Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1 Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1 Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs) Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas Treatment of NF1-related Plexiform Neurofibroma With Trametinib Subtle Myocardial Deformation Abnormalities in Asymptomatic Nf-1 Patients R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1 AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas Neurofibromatosis Type 1 Brain Tumor Genetic Risk Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I Reliability of Functional Outcome Measures in Neurofibromatosis 1 Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1 (NF1) on Clinical Treatment Trials Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach. Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST) Quality of Friendships in Children With Neurofibromatosis Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1) MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Interventions for Reading Disabilities in NF1 Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1 Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain Neurobiology and Treatment of Reading Disability in NF-1 From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1 Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1) Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1 Analysis of Plasma for Diagnosis and Follow-up of Neurofibromatosis Type 1 Study About Annoucement of the Diagnosis of Neurofibromatosis 1 in de Novo Forms MicroRNAs in Patients With Neurofibromatosis Type 1 Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas Stem Cells in NF1 Patients With Tumors of the Central Nervous System Function of the Pigment Epithelium in Patients With Type 1 Neurofibromatosis NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1) Internet Support Group for Parents of a Child With Neurofibromatosis Type 1 Reading Disability in Children With NF1 Multi-center Project: Spinal Abnormalities in Neurofibromatosis Type1 (NF1) Patients Functional Imaging and Reading Deficit in Children With NF1 Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With NF1 Effect of Lamotrigine on Cognition in NF1 A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 Neurofibromatosis Type 1 (NF1) and Tibial Dysplasia Non-invasive Stimulation in Neurofibromatosis Type 1 Modifying Genes in Neurofibromatosis 1 Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1 Vision, Attention and Reading in Neurofibromatosis Type 1 (NF1) Children Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1 Spinal Abnormalities in Neurofibromatosis Type 1 (NF1) Neurofibromatosis Type 1 Patient Registry Frameshift Peptides of Children With NF1 Prevalence of Constitutional Mismatch-repair Deficiency Among Suspected Neurofibromatosis Type 1/Legius Syndrome Children Without a Malignancy and Without a NF1 or SPRED1 Mutation How Neurofibromatosis Type 1 (NF1) Affects Schoolwork and Self-Esteem

Brief Title

Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas

Official Title

A Pilot Study of Sutent®/Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor in Subjects With NF-1 Plexiform Neurofibromas

Brief Summary

      This is a pilot study to determine if adults and children with neurofibromatosis type 1 who
      have plexiform tumors given Sutent® respond to this drug therapy.
    

Detailed Description

      This is an open-label pilot study to evaluate the efficacy of Sutent® in individuals with NF1
      who have clinically significant plexiform tumors. A secondary goal of this study will be to
      seek to improve on current and novel tools to evaluate tumor response of plexiform tumors.
      The rationale for this study arises from the response of human and murine NF1 cells to
      Sutent® in vitro and the clinical response of individuals with NF1 using a similar
      drug,Gleevec®. Following enrollment adult subjects will start receiving Sutent® by month at
      25mg once a day for 28 days. Subjects will then have 14 days without taking any Sutent®. If
      tolerated the dose will be increased to 37.5mg and 50mg with the same regimen (28 days of
      taking medication followed by 14 without). Children will be started on a dose of 10mg/m2/day
      once a day for 28 days. They will then have 14 days without taking any Sutent®. If tolerated
      the dose will be increased to 15mg/m2/day.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Disease Response

Secondary Outcome

 Volumetric Disease Evaluation

Condition

Neurofibromatosis

Intervention

Sutent®/Sunitinib

Study Arms / Comparison Groups

 Sutent®/Sunitinib
Description:  Upon enrollment, subjects will receive Sutent® orally. Adults (Age >18) will receive 25mg. Children will receive 10mg/m2/day. All subjects will take the daily dose for 28 days followed by a 14 day rest period. If subjects tolerate the initial dose, adults will be increased to 37.5mg and children will be increased to 15mg/m2/day. Again, subjects will take that dose for 28 days followed by a rest period of 14 days. Adults who tolerate the increase will go up to the maximum dose of 50mg. The maximum dose for children is 15mg/m2/day.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

19

Start Date

March 2012

Completion Date

February 14, 2018

Primary Completion Date

October 2015

Eligibility Criteria

        Inclusion Criteria:

          1. Age: patients must be ≥3 years of age and ≤65 years of age at the time of study entry

          2. Diagnosis: Patients must meet clinical diagnostic criteria of neurofibromatosis type 1
             (NF1). Patients must have clinically significant plexiform neurofibromas (biopsy
             proven if possible with tissue blocks available). Clinically significant tumors are
             those which are potentially life threatening or are impinging on vital structures or
             significantly impair the quality of life from pain or other symptoms.

          3. Disease status: Patients must have measurable disease.

          4. Performance Level: Karnofsky ≥50 for patients >10 years of age and Lansky ≥50 for
             patients ≤10 years of age. Patients who are unable to walk because of paralysis, but
             who are up in a wheelchair, will be considered ambulatory for the purpose of assessing
             the performance score.

          5. Prior therapy: Patients must have fully recovered from the acute toxic effects of all
             prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.

               1. Myelosuppressive chemotherapy: Must not have received within 3 weeks of entry
                  onto this study.

               2. Hematopoietic growth factors: At least 14 days since completion of therapy with a
                  growth factor.

               3. Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy
                  with a biologic agent. For agents that have known adverse events occurring beyond
                  7 days after administration, the period must be extended beyond the time during
                  which adverse events are known to occur. The duration of this interval must be
                  discussed with the principal investigator.

               4. XRT: ≥2 weeks for local palliative XRT (small port); ≥6 months must have elapsed
                  if ≥50% radiation of pelvis; ≥6 weeks must have elapsed if other substantial BM
                  radiation.

          6. Organ function requirements

             a. Adequate bone marrow function defined as i. Peripheral absolute neutrophil count
             (ANC) ≥1000/µL ii. Platelet count ≥100,000/ µL(transfusion independent, iii.
             Hemoglobin ≥8.0 gm/dL(may receive RBC transfusions) b. Adequate renal function defined
             as i. Creatinine clearance or radioisotope GFR ≥70 mL/min/1.73 m2 or ii. A serum
             creatinine based on age/gender as follows (Maximum Serum Creatinine (mg/dL)): Males: 6
             to <10 years:1; 10 to <13 years: 1.2; 13 to <16 years: 1.5; >16 years 1.7. Females: 6
             to <10 years:1; 10 to <13 years 1.2; 13 to <16 years: 1.4; >16 years: 1.4.

             The threshold creatinine values above were derived from the Schwartz formula for
             estimating GFR (Schwartz et al. J. Peds, 106:522, 1985) utilizing child length and
             stature data published by the CDC.

             c. Adequate Liver Function Defined As: i. Total bilirubin (sum of
             conjugated+unconjugated)≤1.5 times upper limit of normal (ULN) for age, and ii.
             SGPT(ALT)<2.5 upper limit of normal ULN). For the purpose of this study, the ULN for
             SGPT is 45 U/L iii. Serum albumin ≥2 g/dL d. Adequate cardiac function defined as: i.
             Shortening fraction or ejection fraction greater than the LLN (institutional norm),
             and ii. Corrected QT interval ≤450 msec e. Normal Pancreatic function defined as: i.
             Serum amylase ≤1.5xULN and ii. Serum lipase ≤1.5xULN. f. Blood pressure within the
             upper limit of normal defined as: i. A blood pressure (BP) ≤ 95th percentile for age,
             height, and gender and not receiving medication for treatment of hypertension.

          7. Informed Consent: All patients and/or their parents or legal guardians must sign a
             written informed consent. Assent, when appropriate, will be obtained according to
             institutional guidelines.

             -

        Exclusion Criteria:

          1. Prior anthracycline treatment. Patients previously treated with anthracyclines (any
             dose) are not eligible.

          2. Prior Cardiac Radiation Patients previously treated with a radiation field that
             included the heart are not eligible.

          3. Pregnancy or Breast-Feeding Animal studies indicate an increased risk of death of
             pregnant female rats and rabbits exposed to Sutent®. Cleft lip and palate were
             observed in some fetuses exposed in utero to sunitinib. There is yet no available
             information regarding human fetal or teratogenic toxicities. Pregnancy tests must be
             obtained in girls who are poet-menarchal. Males or females of reproductive potential
             may not participate unless they have agreed to use an effective contraceptive method.

          4. Concomitant Medications

               1. Growth factors(s): Growth factors that support platelet or white cell number or
                  function must not have been administered within the past 14 days

               2. Investigational Drugs: Patients who are currently receiving another
                  investigational drug.

               3. Anti-cancer agents: Patients who are currently receiving other anti-cancer
                  agents.

               4. The following CYP3A4 inducers are prohibited 12 days before the start of Sutent®
                  and during the study with Sutent®: rifampin, rifabutin, carbamazepine,
                  Phenobarbital, phenytoin, St. John's wort, efavirenz, and tipranavir.

               5. Anti-thrombotic and anti-platelet agents: warfarin (Coumadin), heparin, low
                  molecular weight heparin, aspirin, and/or ibuprofen, or other NSAIDs.

               6. The following CYP3A4 inhibitors are prohibited 7 days before the start of
                  sunitinib and during the study with sunitinib: azole antifungals (itraconazole,
                  ketoconazole); clarithromycin, erythromycin, diltiazem, verapamil, HIV protease
                  inhibitors (indinavir, saquinavir, ritonavir, atazanavir, nelfinavir);
                  delavirdine.

          5. Infection: Patients who have an uncontrolled infection.

          6. Pleural-based tumors: Pediatric patients treated on a phase II trial with imatinib had
             a higher than expected rate of hemorrhagic pleural effusions. Sutent® inhibits two of
             the same receptor tyrosine kinases as imatinib, PDGFR and c-KIT. Patients with tumors
             involving or abutting the pleural surface will be excluded from study. Patients with
             pulmonary lesions should be monitored closely for the development of hemorrhagic
             pleural effusions.

          7. Patient size: Due to dosing limitations, patients with body surface area <0.5 m2 will
             be excluded from study.

          8. Patients with a pre-existing thyroid abnormality (hyper-or hypothyroidism) with
             unstable thyroid function will be excluded from study. For the purposes of this study,
             unstable thyroid function will be defined as thyroid function abnormalities requiring
             more than on e change in thyroid medication in the 6 months prior to study entry.

          9. Patients with history of allergic reaction attributed to Sutent® or component of
             Sutent® capsules.

         10. Prior use of Sutent®: Patients who have previously received sunitinib are not eligible
             for study.

         11. Patients who in the opinion of the investigator may not be able to comply with the
             safety monitoring requirements of the study.

         12. Patient is < 5 years free of another primary malignancy except if the other primary
             malignancy is not currently clinically significant nor requiring active intervention,
             or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in
             situ. Existence of any other malignant disease is not allowed.

         13. Patient with Grade III/IV cardiac problems as defined by the New York Heart
             Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6
             months of study)

         14. Patient has a severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes,
             chronic renal disease, or active uncontrolled infection).

         15. Patient has a known brain metastasis. Non-specific CNS changes on MRI/CT
             characteristic of NF1 are allowed, but not known CNS malignancies.

         16. Patient has known chronic liver disease (i.e., chronic active hepatitis, and
             cirrhosis).

         17. Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.

         18. Patient had a major surgery within 2 weeks prior to study entry.

             -
      

Gender

All

Ages

3 Years - 65 Years

Accepts Healthy Volunteers

No

Contacts

Chie-Schin Shih, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT01402817

Organization ID

1104-07


Responsible Party

Principal Investigator

Study Sponsor

Indiana University

Collaborators

 United States Department of Defense

Study Sponsor

Chie-Schin Shih, MD, Principal Investigator, Indiana University


Verification Date

February 2018